BROOKLYN, N.Y. — Opentrons Labworks, Inc., a leader in lab automation and makers of accessible lab robotics, today announced the appointment of Gregory Cole, PhD as Chief Innovation Officer. With over a decade of medical robotics, IP strategy, and product commercialization expertise, Dr. Cole will be responsible for establishing commercial and academic partnerships with leading research institutions and biopharma companies and creating novel product solutions for the company’s Opentrons Flex, the first liquid-handling robot designed to be compatible with “design-of-experiment” programs, including AI-driven agents utilizing large language models (LLMs).

“Greg’s remarkable experience underscores his proficiency in steering robotic technologies towards successful commercialization,” said Jonathan Brennan-Badal, CEO of Opentrons. “With a proven history of advancing medical robotics and fostering corporate partnerships, he will play a pivotal role in driving the continued global reach of Opentrons Flex and delivering innovative automated solutions to life science researchers. We welcome Greg to the Opentrons family.”

Dr. Cole served as Chief Technology Officer and Advisor at AiM Medical Robotics, responsible for developing and manufacturing image-guided robotic surgical devices and R&D platforms. He was also VP, Engineering and Field Services at MineSense Corporation, where he scaled solutions for comprehensive hardware and software systems, product development structure, and engineering organization development. Dr. Cole holds a PhD in Robotics Engineering from Worcester Polytechnic Institute.

“Opentrons is propelling automated lab robotics to new heights in scientific research. The opportunity to leverage Opentrons’ technology for laboratory automation will fast-track scientific discoveries, providing an unmatched level of efficiency and precision without compromising on accuracy. I’m looking forward to bringing my expertise in engineering to help them advance Opentrons Flex and other automated solutions,” said Dr. Cole.

About Opentrons:

Opentrons Labworks, Inc., a disruptive life science company and the current market leader in entry-level lab automation, accelerates innovation in research and healthcare through its integrated lab platform, which includes business units Opentrons Robotics and Neochromosome. Opentrons has raised over $200 million in funding and achieved unicorn status based on its first- and second-generation robots, OT-One and OT-2. The recently launched Opentrons Flex is Opentrons’ next generation of liquid-handling lab robots, offering open-source accessibility and compatibility with generative AI tools. Opentrons Robotics provides thousands of institutions with flexible, easy-to-use lab robots, automating R&D operations and making robotics, a vast open-source library accessible to life sciences researchers worldwide. Opentrons is used in labs at the top 20 academic universities in the US and 14 of 15 leading global biopharmaceutical companies. Learn more at https://opentrons.com/.